Hot Stocks: Brokerage firms on Godrej Consumer, DLF, Zydus Life and Biocon – Heemang Parmar

Brokerage firm Goldman Sachs maintained a buy rating on Godrej Consumer, JPMorgan has an overweight rating on DLF, Axis Capital maintained a buy rating on Zydus Life, and Morgan Stanley retained its overweight stance on Biocon.

We have collated a list of recommendations from top brokerage firms from ETNow and other sources:

Goldman Sachs on Godrej Consumer: Buy| Target Rs 1100
Goldman Sachs maintained a buy rating on Godrej Consumer with a target of Rs 1100. Turnaround is likely to gather momentum as the reset phase is behind, said the note.

Hair colours, air care, and liquid detergents are some of the products which could boost the baseline for the company. International business is also poised for some recovery, the note highlighted.

JPMorgan on DLF: Overweight| Target Rs 490
JPMorgan maintained an overweight rating on DLF with a target price of Rs 490. The company announced the sale of its most important launch of FY23.

The realty player is expecting a gradual sales recovery over three years with a 30-50% sales at launch.

The company said that 95% of the buyers are individual end users. “We believe that the company will regain its long-lost slot,” said the note.Axis Capital on Zydus Life: Buy| Target Rs 560
Axis Capital maintained a buy rating on Zydus Life with a target price of Rs 560. The US markets could see new launches which will improve growth visibility, said the note.

“India to see steady growth visibility. R&D to assets is likely to drive long-term growth. The company tweaked EPS estimates for FY24/25E,” the note added.

Morgan Stanley on Biocon: Overweight| Target Rs 311
Morgan Stanley maintained an overweight rating on Biocon with a target price of Rs 311. The global investment bank expects that the share price will rise in absolute terms over the next 15 days.

The stock traded off recently, making short-term valuations much more compelling. The stock has corrected by over 28% on a year-to-date basis compared to the 2.8% fall seen in the S&P BSE Sensex.

Potential PE investment in Biocon Biologics Limited (BBL) is leading to some debt reduction which is a positive sign, it said.

(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)